James Trager – VJRegenMed

Allogenic NKX101 in r/r AML

admin_vjr_user — Tue, 22 Jun 2021 13:58:16 +0000

James Trager, PhD, NKarta Therapeutics, South San Francisco, CA describes the ongoing Phase I clinical trial (NCT04623944) of NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, in patients with relapsed/refractory acute myeloid leukemia (AML). The study aims to examine NKX101 monotherapy derived from both human leukocyte antigen (HLA)-matched and unmatched donors in order to investigate the role of HLA matching and the potential of developing a broad, non-matched off-the-shelf program that enables the selection of donors with enhanced NK cell activity and manufacturability. This interview took place during the CAR-TCR Summit Europe 2021.

Targetting cancer with allogeneic NK cell therapies

admin_vjr_user — Wed, 24 Mar 2021 19:15:28 +0000

James Trager, PhD, NKarta Therapeutics, South San Francisco, CA, provides an overview of his presentation at the CAR-TCR Summit Europe 2021 on the use of engineered natural killer (NK) cells for allogeneic therapy and describes NKX019, an allogeneic CD19-directed chimeric antigen receptor (CAR)-engineered NK cell, which is being studied preclinically in B cell malignancies. CAR-NK cells have been demonstrated to posses a greater inherent cytotoxicity and reduced risk of cytokine release syndrome compared to CAR-T cells. He also introduces a novel strategy currently under preclinical investigation which involves combining NK and T-cell modalities due to their synergistic properties. This interview took place during the CAR-TCR Summit Europe 2021.

CAR-NKs for B cell malignancies

admin_vjr_user — Wed, 24 Mar 2021 19:15:25 +0000

James Trager, PhD, NKarta Therapeutics, South San Francisco, CA, describes NKX019, an investigational allogeneic natural killer (NK) cell-based cancer immunotherapy expanded from healthy donor blood and engineered with a chimeric antigen receptor (CAR) that targets tumors expressing the CD19 antigen for the treatment of B-cell malignancies. NKX019 is also engineered with membrane-bound form of the IL15 cytokine which has been demonstrated to enhance the proliferation and persistence of NK cells in preclinical models. This interview took place during the CAR-TCR Summit Europe 2021.